Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia

Rika Kizu, Kazuko Nishimura, Reiko Sato, Kenjiro Kosaki, Toshiaki Tanaka, Yusuke Tanigawara, Tomonobu Hasegawa

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Diazoxide is the first-line treatment for pediatric hyperinsulinemic hypoglycemia (HI). This study aimed to elucidate the pharmacokinetics of diazoxide in children with HI. Methods: We obtained 81 blood samples from 22 children with HI. Measured serum diazoxide concentrations were used for population pharmacokinetic analysis. Patient factors influencing pharmacokinetics were estimated using nonlinear mixed-effects model analysis. Relationships between drug exposure and adverse drug reactions were also investigated. Results: Diazoxide disposition in the body was described by a 1-compartment model. Oral clearance (CL/F) and the volume of distribution were proportional to body weight (WT), as expressed by CL/F in males (liters/h) = 0.0358 + 0.00374 × WT (kg). CL/F in females was 39% greater than that in males. Steady-state concentrations of diazoxide were similar following twice- and 3 times-daily dosing when the total daily doses were comparable. A patient whose serum diazoxide concentration exceeded 100 μg/mL over a 4-month period developed hyperglycemia. No significant correlation was observed between severity of hirsutism and diazoxide concentration. Conclusion: We have proposed for the first time a population pharmacokinetic model for diazoxide in children with HI. The potential risk of diabetes mellitus and/or hyperglycemia increases when serum concentrations of diazoxide exceed 100 μg/mL.

Original languageEnglish
JournalHormone Research in Paediatrics
DOIs
Publication statusAccepted/In press - 2017 Jul 14

Fingerprint

Diazoxide
Hypoglycemia
Pharmacokinetics
Population
Hyperglycemia
Serum
Hirsutism
Drug-Related Side Effects and Adverse Reactions
Diabetes Mellitus
Body Weight
Pediatrics
Weights and Measures

Keywords

  • Diazoxide
  • Hyperinsulinemic hypoglycemia
  • Population pharmacokinetics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia. / Kizu, Rika; Nishimura, Kazuko; Sato, Reiko; Kosaki, Kenjiro; Tanaka, Toshiaki; Tanigawara, Yusuke; Hasegawa, Tomonobu.

In: Hormone Research in Paediatrics, 14.07.2017.

Research output: Contribution to journalArticle

@article{525363b72e8d4492b99051ca45baf755,
title = "Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia",
abstract = "Background: Diazoxide is the first-line treatment for pediatric hyperinsulinemic hypoglycemia (HI). This study aimed to elucidate the pharmacokinetics of diazoxide in children with HI. Methods: We obtained 81 blood samples from 22 children with HI. Measured serum diazoxide concentrations were used for population pharmacokinetic analysis. Patient factors influencing pharmacokinetics were estimated using nonlinear mixed-effects model analysis. Relationships between drug exposure and adverse drug reactions were also investigated. Results: Diazoxide disposition in the body was described by a 1-compartment model. Oral clearance (CL/F) and the volume of distribution were proportional to body weight (WT), as expressed by CL/F in males (liters/h) = 0.0358 + 0.00374 × WT (kg). CL/F in females was 39{\%} greater than that in males. Steady-state concentrations of diazoxide were similar following twice- and 3 times-daily dosing when the total daily doses were comparable. A patient whose serum diazoxide concentration exceeded 100 μg/mL over a 4-month period developed hyperglycemia. No significant correlation was observed between severity of hirsutism and diazoxide concentration. Conclusion: We have proposed for the first time a population pharmacokinetic model for diazoxide in children with HI. The potential risk of diabetes mellitus and/or hyperglycemia increases when serum concentrations of diazoxide exceed 100 μg/mL.",
keywords = "Diazoxide, Hyperinsulinemic hypoglycemia, Population pharmacokinetics",
author = "Rika Kizu and Kazuko Nishimura and Reiko Sato and Kenjiro Kosaki and Toshiaki Tanaka and Yusuke Tanigawara and Tomonobu Hasegawa",
year = "2017",
month = "7",
day = "14",
doi = "10.1159/000478696",
language = "English",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Population Pharmacokinetics of Diazoxide in Children with Hyperinsulinemic Hypoglycemia

AU - Kizu, Rika

AU - Nishimura, Kazuko

AU - Sato, Reiko

AU - Kosaki, Kenjiro

AU - Tanaka, Toshiaki

AU - Tanigawara, Yusuke

AU - Hasegawa, Tomonobu

PY - 2017/7/14

Y1 - 2017/7/14

N2 - Background: Diazoxide is the first-line treatment for pediatric hyperinsulinemic hypoglycemia (HI). This study aimed to elucidate the pharmacokinetics of diazoxide in children with HI. Methods: We obtained 81 blood samples from 22 children with HI. Measured serum diazoxide concentrations were used for population pharmacokinetic analysis. Patient factors influencing pharmacokinetics were estimated using nonlinear mixed-effects model analysis. Relationships between drug exposure and adverse drug reactions were also investigated. Results: Diazoxide disposition in the body was described by a 1-compartment model. Oral clearance (CL/F) and the volume of distribution were proportional to body weight (WT), as expressed by CL/F in males (liters/h) = 0.0358 + 0.00374 × WT (kg). CL/F in females was 39% greater than that in males. Steady-state concentrations of diazoxide were similar following twice- and 3 times-daily dosing when the total daily doses were comparable. A patient whose serum diazoxide concentration exceeded 100 μg/mL over a 4-month period developed hyperglycemia. No significant correlation was observed between severity of hirsutism and diazoxide concentration. Conclusion: We have proposed for the first time a population pharmacokinetic model for diazoxide in children with HI. The potential risk of diabetes mellitus and/or hyperglycemia increases when serum concentrations of diazoxide exceed 100 μg/mL.

AB - Background: Diazoxide is the first-line treatment for pediatric hyperinsulinemic hypoglycemia (HI). This study aimed to elucidate the pharmacokinetics of diazoxide in children with HI. Methods: We obtained 81 blood samples from 22 children with HI. Measured serum diazoxide concentrations were used for population pharmacokinetic analysis. Patient factors influencing pharmacokinetics were estimated using nonlinear mixed-effects model analysis. Relationships between drug exposure and adverse drug reactions were also investigated. Results: Diazoxide disposition in the body was described by a 1-compartment model. Oral clearance (CL/F) and the volume of distribution were proportional to body weight (WT), as expressed by CL/F in males (liters/h) = 0.0358 + 0.00374 × WT (kg). CL/F in females was 39% greater than that in males. Steady-state concentrations of diazoxide were similar following twice- and 3 times-daily dosing when the total daily doses were comparable. A patient whose serum diazoxide concentration exceeded 100 μg/mL over a 4-month period developed hyperglycemia. No significant correlation was observed between severity of hirsutism and diazoxide concentration. Conclusion: We have proposed for the first time a population pharmacokinetic model for diazoxide in children with HI. The potential risk of diabetes mellitus and/or hyperglycemia increases when serum concentrations of diazoxide exceed 100 μg/mL.

KW - Diazoxide

KW - Hyperinsulinemic hypoglycemia

KW - Population pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=85025472161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025472161&partnerID=8YFLogxK

U2 - 10.1159/000478696

DO - 10.1159/000478696

M3 - Article

C2 - 28715810

AN - SCOPUS:85025472161

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

ER -